Nandini Menon

2.0k total citations
134 papers, 582 citations indexed

About

Nandini Menon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Nandini Menon has authored 134 papers receiving a total of 582 indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Pulmonary and Respiratory Medicine, 56 papers in Oncology and 25 papers in Surgery. Recurrent topics in Nandini Menon's work include Lung Cancer Treatments and Mutations (38 papers), Head and Neck Cancer Studies (18 papers) and Lung Cancer Research Studies (17 papers). Nandini Menon is often cited by papers focused on Lung Cancer Treatments and Mutations (38 papers), Head and Neck Cancer Studies (18 papers) and Lung Cancer Research Studies (17 papers). Nandini Menon collaborates with scholars based in India, United States and United Kingdom. Nandini Menon's co-authors include Kumar Prabhash, Vanita Noronha, Vijay Patil, Amit Joshi, Abhishek Mahajan, Akhil Kapoor, Amit Joshi, Rajiv Kumar, George Abraham and Sachin Dhumal and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Nandini Menon

109 papers receiving 550 citations

Peers

Countries citing papers authored by Nandini Menon

Since Specialization

Citations

This map shows the geographic impact of Nandini Menon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nandini Menon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nandini Menon more than expected).

Fields of papers citing papers by Nandini Menon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nandini Menon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nandini Menon. The network helps show where Nandini Menon may publish in the future.

Co-authorship network of co-authors of Nandini Menon

This figure shows the co-authorship network connecting the top 25 collaborators of Nandini Menon. A scholar is included among the top collaborators of Nandini Menon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nandini Menon. Nandini Menon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME) 2025 ·Cancer Medicine ·Archya Dasgupta, (unknown), (unknown), Vikram Gota, (unknown), (unknown), (unknown), Ameya Puranik, (unknown), Aliasgar Moiyadi, Prakash Shetty, (unknown), Nandini Menon, Sridhar Epari, Ayushi Sahay, (unknown), (unknown), (unknown), (unknown), Tejpal Gupta	1
2	Nutritional status and impact on outcomes of patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: a pre-planned secondary analysis of a phase 3 randomized controlled trial 2025 ·Journal of the Egyptian National Cancer Institute ·(unknown), (unknown), (unknown), Nandini Menon, (unknown), Supriya Goud, Sucheta More, (unknown), Vijayalakshmi Mathrudev, (unknown)	0
3	Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience 2025 ·PubMed ·Prerana Jha, Rohit Mishra, (unknown), Neha Sharma, (unknown), Govind Babu, Amit Rauthan, Sewanti Limaye, Nandini Menon, (unknown), Vanita Noronha, (unknown), Kumar Prabhash	1
4	Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings 2024 ·PubMed ·Amit Kumar, Akhil Kapoor, Vanita Noronha, Vijay Patil, Nandini Menon, Ajay Singh, Amit Joshi, (unknown), Rajiv Kumar, Trupti Pai, Anuradha Chougule, Omshree Shetty, Kumar Prabhash	1
5	Retrospective analysis: Does 5-FU dose adjustment per DPYD mutation status affect toxicity? 2024 ·Journal of Clinical Oncology ·(unknown), Vanita Noronha, Vijay Patil, Nandini Menon, (unknown), (unknown), Kumar Prabhash	0
6	Identification of Rare EIF3E::RSPO2 Fusion in Recurrent and Aggressive Urachal Adenocarcinoma 2024 ·Genes Chromosomes and Cancer ·Prerana Jha, (unknown), (unknown), (unknown), Rohit Mishra, Nandini Menon, (unknown), Santosh Menon, (unknown), Gagan Prakash, Vanita Noronha, Kumar Prabhash, Prashant Kumar	1
7	Clinical Profile and Outcomes of Carcinoma Penis Patients Receiving Systemic Therapy at an Indian tertiary care Center: A Retrospective Observational Study 2024 ·Clinical Genitourinary Cancer ·Vanita Noronha, (unknown), Amit Joshi, Nandini Menon, Ajay Singh, Gagan Prakash, Santosh Menon, Nilesh Sable, (unknown), Mahendra Pal, Amandeep Arora, (unknown), Shripad Banavali, Kumar Prabhash	1
8	Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients 2024 ·Clinical Lung Cancer ·Prerana Jha, (unknown), Rohit Mishra, (unknown), (unknown), Sewanti Limaye, Govind Babu, Ullas Batra, Prabhat Singh Malik, Rajiv Kumar, (unknown), Nandini Menon, Amit Rauthan, Moni Abraham Kuriakose, (unknown), Vanita Noronha, (unknown), Kumar Prabhash	2
9	Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India 2024 ·SHILAP Revista de lepidopterología ·(unknown), Ajay Singh, Vanita Noronha, (unknown), Nandini Menon, (unknown), (unknown), (unknown), (unknown), (unknown), Shashikant Yadav, Anuradha Majumdar, Pratik Chandrani, Rajiv Kumar, Trupti Pai, Amit Janu, (unknown), Kumar Prabhash	0
10	Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma 2023 ·Neuro-Oncology Advances ·Tejpal Gupta, (unknown), Sadhana Kannan, Nandini Menon, Archya Dasgupta, Abhishek Chatterjee	7
11	Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy 2023 ·Gene ·(unknown), Vanita Noronha, Srikanth S. Manda, Rohit Mishra, Pratik Chandrani, Vijay Patil, Nandini Menon, Anuradha Chougule, (unknown), Sewanti Limaye, Moni Abraham Kuriakose, Shripad Banavali, Prashant Kumar, Kumar Prabhash	4
12	Imaging Recommendations for Diagnosis, Staging, and Management of Oral Cancer 2023 ·Indian Journal of Medical and Paediatric Oncology ·Abhishek Mahajan, (unknown), (unknown), Richa Vaish, (unknown), (unknown), Ashu Seith Bhalla, (unknown), Suman Kumar Ankathi, Sarbani Ghosh Laskar, Vijay Patil, Vanita Noronha, Nandini Menon, Kumar Prabhash, (unknown), Asawari Patil, (unknown), Pankaj Chaturvedi, Prathamesh Pai, Anil D′Cruz	5
13	Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre 2022 ·ecancermedicalscience ·(unknown), (unknown), (unknown), Vanita Noronha, Amit Joshi, Vijay Patil, Nandini Menon, Rajiv Kumar, Anuradha Choughule, Sabita Jiwnani, (unknown), Kumar Prabhash	0
14	Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India 2022 ·ecancermedicalscience ·Vijay Patil, George Abraham, (unknown), Atanu Bhattacharjee, Vanita Noronha, (unknown), Nandini Menon, Jyoti Bajpai, Kumar Prabhash	4
15	Outcomes of Ewing sarcoma in adults over 40 years of age from a low-middle income country 2022 ·ecancermedicalscience ·(unknown), Arun Chandrasekharan, (unknown), Prabhat Bhargava, Sujay Srinivas, Siddhartha Laskar, Smruti Mokal, Bharat Rekhi, Nehal Khanna, Nandini Menon, Vijay Patil, Vanita Noronha, Amit Joshi, Kumar Prabhash, Shripad Banavali, Sudeep Gupta, Jyoti Bajpai	4
16	Immune checkpoint inhibitors in patients with solid tumors and poor performance status 2021 ·Medicine ·Akhil Kapoor, Vanita Noronha, (unknown), Nandini Menon, Amit Joshi, George Abraham, Kumar Prabhash	6
17	Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation – a phase 3 study 2021 ·ecancermedicalscience ·Amit Joshi, (unknown), Vanita Noronha, Atanu Bhattacharjee, Nandini Menon, Amit Kumar, (unknown), (unknown), (unknown), (unknown), (unknown), Amit Agarwal, (unknown), (unknown), (unknown), (unknown), Kishore Das, Vikas Talreja, Sachin Dhumal, Kumar Prabhash	2
18	Weight loss and its impact on outcome in head and cancer patients during chemo-radiation 2021 ·Oral Oncology ·Gunjesh Kumar Singh, Vijay Patil, Vanita Noronha, Amit Joshi, Nandini Menon, (unknown), Vijayalakshmi Mathrudev, (unknown), Kumar Prabhash	4
19	393P Financial toxicity in patients undergoing systemic therapy in brain tumours: A cross-sectional study 2020 ·Annals of Oncology ·D. Kalra, Gunjesh Kumar Singh, Nandini Menon, Vijai Simha, (unknown), (unknown), Lakshmana Das, (unknown), (unknown), Vijay Patil	0
20	345P Thromboembolic events in brain tumour patients on bevacizumab 2020 ·Annals of Oncology ·Gunjesh Kumar Singh, Nandini Menon, (unknown), (unknown), (unknown), Surendra Roy, Sudipta Das, (unknown), (unknown), Vijay Patil	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact